BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1980 related articles for article (PubMed ID: 25977461)

  • 1. In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET.
    Niedermoser S; Chin J; Wängler C; Kostikov A; Bernard-Gauthier V; Vogler N; Soucy JP; McEwan AJ; Schirrmacher R; Wängler B
    J Nucl Med; 2015 Jul; 56(7):1100-5. PubMed ID: 25977461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next Generation of SiFAlin-Based TATE Derivatives for PET Imaging of SSTR-Positive Tumors: Influence of Molecular Design on In Vitro SSTR Binding and In Vivo Pharmacokinetics.
    Litau S; Niedermoser S; Vogler N; Roscher M; Schirrmacher R; Fricker G; Wängler B; Wängler C
    Bioconjug Chem; 2015 Dec; 26(12):2350-9. PubMed ID: 26420336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution and first clinical results of
    Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of a high-affinity 18F-trifluoroborate octreotate derivative for somatostatin receptor imaging.
    Liu Z; Pourghiasian M; Bénard F; Pan J; Lin KS; Perrin DM
    J Nucl Med; 2014 Sep; 55(9):1499-505. PubMed ID: 24970911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-step ¹⁸F-labeling of carbohydrate-conjugated octreotate-derivatives containing a silicon-fluoride-acceptor (SiFA): in vitro and in vivo evaluation as tumor imaging agents for positron emission tomography (PET).
    Wängler C; Waser B; Alke A; Iovkova L; Buchholz HG; Niedermoser S; Jurkschat K; Fottner C; Bartenstein P; Schirrmacher R; Reubi JC; Wester HJ; Wängler B
    Bioconjug Chem; 2010 Dec; 21(12):2289-96. PubMed ID: 21082773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microscale radiosynthesis, preclinical imaging and dosimetry study of [
    Lisova K; Sergeev M; Evans-Axelsson S; Stuparu AD; Beykan S; Collins J; Jones J; Lassmann M; Herrmann K; Perrin D; Lee JT; Slavik R; van Dam RM
    Nucl Med Biol; 2018 Jun; 61():36-44. PubMed ID: 29747035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiosynthesis of [
    Lindner S; Wängler C; Bailey JJ; Jurkschat K; Bartenstein P; Wängler B; Schirrmacher R
    Nat Protoc; 2020 Dec; 15(12):3827-3843. PubMed ID: 33230332
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Gao F; Zhang Y; Chen M; Song Z; Dong R; Qiu S; Shen C; Huang X; Geng H; Cheng W; Hu J
    Eur J Pharm Sci; 2024 Feb; 193():106671. PubMed ID: 38104907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3p-C-NETA: A versatile and effective chelator for development of Al
    Ahenkorah S; Murce E; Cawthorne C; Ketchemen JP; Deroose CM; Cardinaels T; Seimbille Y; Fonge H; Gsell W; Bormans G; Ooms M; Cleeren F
    Theranostics; 2022; 12(13):5971-5985. PubMed ID: 35966589
    [No Abstract]   [Full Text] [Related]  

  • 11. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
    Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
    J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Boeckxstaens L; Dekervel J; Vandamme T; Lybaert W; den Broeck BV; Laenen A; Clement PM; Geboes K; Cutsem EV; Stroobants S; Verslype C; Bormans G; Deroose CM
    J Nucl Med; 2023 Apr; 64(4):632-638. PubMed ID: 36265911
    [No Abstract]   [Full Text] [Related]  

  • 14. Radiosynthesis and Preclinical Evaluation of
    Maschauer S; Heilmann M; Wängler C; Schirrmacher R; Prante O
    Bioconjug Chem; 2016 Nov; 27(11):2707-2714. PubMed ID: 27715017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE.
    Velikyan I; Xu H; Nair M; Hall H
    Nucl Med Biol; 2012 Jul; 39(5):628-39. PubMed ID: 22336375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective head-to-head comparison of
    Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhu Z
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4218-4227. PubMed ID: 35657429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [
    Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Dekervel J; Van Cutsem E; Verslype C; Van Laere K; Bormans G; Deroose CM
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3033-3046. PubMed ID: 32617641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 99.